100× faster
Results in hours, not the weeks a centralized sequencing workflow requires.
The frequency imperative.
Timing can matter as much as sensitivity.
LBx Bio is developing a compact biomarker monitoring platform designed to increase surveillance cadence in the intervals between centralized lab tests — surfacing rising molecular signals earlier, then routing them into timely confirmatory testing through existing clinical workflows.
We are beginning in oncology, where earlier visibility into recurrence could accelerate follow-up and care decisions.
100× lower cost
Per-test economics that make frequent monitoring the norm, not the exception.
25× more often
Monitoring cadence set by disease biology, not laboratory logistics.
25+ biomarkers, multiplexed
Multi-analyte measurement across a broader disease signal set, from a single draw.
Figures reflect target performance for the investigational platform, benchmarked against centralized NGS workflows.